AbbVie 2025年管线更新-AbbVie Pipeline Update介绍.docx

AbbViePipeline

January2025

Update

AbbVieRDPipeline

Phase1

.CUG-252*(IL-2Mutein)SLE.ABBV-8736(TREM1)IBD

.Livmoniplimab(GARP+TGFβ1)SolidTumors.Temab-A(ABBV-400)(c-MetADC)NSCLC

.ABBV-706(SEZ6ADC)SCLC

.ABBV-CLS-579*(PTPN2)SolidTumors.ABBV-CLS-484*(PTPN2)SolidTumors.ABBV-514(CCR8)SolidTumors

.ABBV-303(c-MetTRINKET)SolidTumors.ABBV-969(PSMA/STEAP1ADC)mCRPC.IMGN-151(FRαADC)OvarianCancer

.IMGN-151(FRαADC)EndometrialCancer.UB-VV111*(CD19)HemeTumors

.Etentamig(ABBV-383)(CD3-BCMA)

R/RMMCombinations

.Etentamig(ABBV-383)(CD3-BCMA)

ALAmyloidosis

.ABBV-319(CD19/SteroidADC)HemeTumors.ABBV-525(MALT1)HemeTumors

.ABBV-453(BCL-2)R/RMMt(11;14)/BCL2High.ABBV-453(BCL-2)R/RCLL

.Epkinly*(CD3-CD20)R/RCLLandRichter’sSyndrome

.ABBV-101(BTKDegrader)R/RNHL

.ABBV-CLS-7262*(elF2B)VWMDisease

.ABBV-CLS-7262*(elF2B)MDD

.ABBV-1088(PINK1)Parkinson’sDisease.ABBV-1758(3pE-Aβ)Alzheimer’sDisease.Emraclidine(M4PAM)ADPsychosis

.ABBV-1354(KORAntagonist)Depression

.ABBV-141(LPAR1)SScIPF.ABBV-142(LPAR1)SScIPF.ABBV-722(LPAR1)SScIPF

.Lutikizumab(IL-1α/1β)UC

.Lutikizumab(IL-1α/1β)AtopicDermatitis.Lutikizumab(IL-1α/1β)+Skyrizi*(IL-23)CD

.ABBV-382(α4β7)+Skyrizi*(IL-23)CD.OpSCF*(StemCellFactormAb)AD

.ABBV-113(NLRX1)UC

.Epkinly*(CD3-CD20)B-CellNHL

.Temab-A(ABBV-400)(c-MetADC)1LGEA.Livmoniplimab(GARP+TGFβ1)1LHCC

.Livmoniplimab(GARP+TGFβ1)2LHCC.Livmoniplimab(GARP+TGFβ1)1LNSCLC.Livmoniplimab(GARP+TGFβ1)2L+mUC

.TTX-030*(CD39)PancreaticCancer.Budigalimab(PD-1)SolidTumors.Elahere(FRαADC)PSOC(420)

.PivekimabSunirine(CD123ADC)AML

.Emraclidine(M4PAM)Schizophrenia

.ABBV-932*(D2/D3Agonist)BipolarDisorder.BotoxEssentialTremor

.Elezanumab(RGMa)SpinalCordInjury

.Darigabat(GABAAPAM)PanicDisorder

.ABBV-RGX-314*(NAVAAV8Anti-VEGFFab)

wAMDSuprachoroidalDelivery

.